[Urinary evaluation of 5-S-cysteinyldopa and seric evaluation of IgG4 subclass during follow-up of 27 primitive malignant melanomas (author's transl)].
27 patients with SSM or NM level IV and V have been submitted to a monthly evaluation of their level of 5-S-cysteinyldopa in the urine and IgG4 subclass in their sera. For 5 patients who entered the stage II of their disease during the follow-up, 3 had elevation of the 5S and 5 had large variations of IgG4. On 21 patients in clinical remission, 10 had conjunctly an increase of 5S and variations of IgG4. The predictional value of these tests is discussed.
D003548:Cysteinyldopa / Q000652:urine*; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism; D009362:Neoplasm Metastasis
D007074:Immunoglobulin G; D003548:Cysteinyldopa; D004295:Dihydroxyphenylalanine
Dosage urinaire de la 5-S-cystéinyldopa et dosage sérique de la sous-classe IgG4 au cours de la surveillance de 27 cas de mélanomes malins primitifs.